Employee-Paid

The Delinking Revenue from Unfair Gouging (DRUG) Act would require pharmacy benefit managers that contract with a carrier offering federal health benefits plans to "de-link" the fees they charge insurers from the price of drugs.  

Only about 3 in 10 believe the quality of care and services they receive reflect their costs.

As part of the negotiated settlement, the defendants paid more than $8.3 million in restitution.

The Biden administration took the first step in its Medicare drug price negotiation program for 10 of the costliest prescription drugs, giving drugmakers until March 2 to either accept the government's offer or make a counteroffer.

While there is no system in place to equitably manage the patient-to-clinician ratio across every state, the system counts only physicians, not the myriad other health care professionals who now provide the nation's primary care.

The Federal Trade Commission launched its inquiry of the 6 largest PBMs in June 2022, after Sen. Chuck Grassley (R-Iowa) had pressed the commission for years to review their role in determining prices for prescriptions like insulin.